160 related articles for article (PubMed ID: 25349884)
1. Differential clinical outcomes after 1 year vs. 5 years in the SORTOUT III randomized comparison of zotarolimus- and sirolimus-eluting coronary stents.
Maeng M
Eur Heart J; 2014 Sep; 35(35):2340-1. PubMed ID: 25349884
[No Abstract] [Full Text] [Related]
2. Zotarolimus-eluting vs. sirolimus-eluting coronary stents in patients with and without acute coronary syndromes: a SORT OUT III substudy.
Thim T; Maeng M; Kaltoft A; Jensen LO; Tilsted HH; Hansen PR; Kelbaek H; Thayssen P; Ravkilde J; Madsen M; Sørensen HT; Thuesen L; Lassen JF
Eur J Clin Invest; 2012 Oct; 42(10):1047-54. PubMed ID: 22624990
[TBL] [Abstract][Full Text] [Related]
3. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
[TBL] [Abstract][Full Text] [Related]
4. TCT Daily: ZOMAXX I--mixed results with zotarolimus-eluting stent.
J Interv Cardiol; 2007 Feb; 20(1):35. PubMed ID: 17300399
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of zotarolimus-eluting stents compared with sirolimus-eluting stents in patients undergoing percutaneous coronary interventions--a meta-analysis of randomized controlled trials.
Fan J; Du H; Yin Y; Ling Z; Wu J; Xiao P; Zrenner B
Int J Cardiol; 2013 Sep; 167(5):2126-33. PubMed ID: 22703941
[TBL] [Abstract][Full Text] [Related]
6. Could Paclitaxel-eluting stents be superior to sirolimus-eluting stents for the treatment of saphenous vein graft lesions?
Brilakis ES; Banerjee S
Am J Cardiol; 2010 Nov; 106(9):1367-8. PubMed ID: 21029842
[No Abstract] [Full Text] [Related]
7. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
[TBL] [Abstract][Full Text] [Related]
8. Understanding the drug-eluting stent trials.
Coolong A; Kuntz RE
Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349
[TBL] [Abstract][Full Text] [Related]
9. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial.
Kandzari DE; Leon MB; Popma JJ; Fitzgerald PJ; O'Shaughnessy C; Ball MW; Turco M; Applegate RJ; Gurbel PA; Midei MG; Badre SS; Mauri L; Thompson KP; LeNarz LA; Kuntz RE;
J Am Coll Cardiol; 2006 Dec; 48(12):2440-7. PubMed ID: 17174180
[TBL] [Abstract][Full Text] [Related]
10. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?
Buellesfeld L; Grube E
Herz; 2004 Mar; 29(2):167-70. PubMed ID: 15054589
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
Grube E; Buellesfeld L
Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
Stone GW; Moses JW; Ellis SG; Schofer J; Dawkins KD; Morice MC; Colombo A; Schampaert E; Grube E; Kirtane AJ; Cutlip DE; Fahy M; Pocock SJ; Mehran R; Leon MB
N Engl J Med; 2007 Mar; 356(10):998-1008. PubMed ID: 17296824
[TBL] [Abstract][Full Text] [Related]
15. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Eisenstein EL; Leon MB; Kandzari DE; Mauri L; Edwards R; Kong DF; Cowper PA; Anstrom KJ;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1199-207. PubMed ID: 20129546
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV).
Jensen LO; Thayssen P; Hansen HS; Christiansen EH; Tilsted HH; Krusell LR; Villadsen AB; Junker A; Hansen KN; Kaltoft A; Maeng M; Pedersen KE; Kristensen SD; Bøtker HE; Ravkilde J; Sanchez R; Aarøe J; Madsen M; Sørensen HT; Thuesen L; Lassen JF;
Circulation; 2012 Mar; 125(10):1246-55. PubMed ID: 22308301
[TBL] [Abstract][Full Text] [Related]
17. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
[TBL] [Abstract][Full Text] [Related]
18. Drug-eluting stents: from randomized trials to the real world.
Saia F; Degertekin M; Lemos PA; Serruys PW
Minerva Cardioangiol; 2004 Oct; 52(5):349-63. PubMed ID: 15514571
[TBL] [Abstract][Full Text] [Related]
19. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial.
Park DW; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Seong IW; Lee JH; Tahk SJ; Jeong MH; Jang Y; Cheong SS; Yang JY; Lim DS; Seung KB; Chae JK; Hur SH; Lee SG; Yoon J; Lee NH; Choi YJ; Kim HS; Kim KS; Kim HS; Hong TJ; Park HS; Park SJ
J Am Coll Cardiol; 2010 Oct; 56(15):1187-95. PubMed ID: 20883925
[TBL] [Abstract][Full Text] [Related]
20. Clinical experiences using everolimus-eluting stents in patients with coronary artery disease.
Störger H; Grube E; Hofmann M; Schwarz F; Haase J
J Interv Cardiol; 2004 Dec; 17(6):387-90. PubMed ID: 15546290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
